메뉴 건너뛰기
Alimentary Pharmacology and Therapeutics
Volumn 43, Issue 5, 2016, Pages 654-655
Letter: Nucleos(t)ide analogues are good, but not sufficient for hepatitis B virus clearance
Author keywords

[No Author keywords available]
Indexed keywords

ANTIVIRUS AGENT; ENTECAVIR; MYRCLUDEX B; NUCLEOSIDE ANALOG; NUCLEOTIDE DERIVATIVE; RIBONUCLEASE H; UNCLASSIFIED DRUG; GUANINE;
EID: 84962146892     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13502     Document Type: Letter
Times cited : (2)
References (10)
  • 1
    • 84943665286 scopus 로고    scopus 로고
    • Clinical outcomes after interruption of entecavir therapy in HBeAg-negative chronic hepatitis B patients with compensated cirrhosis
    • Chen YC, Peng CY, Jeng WJ, Chien RN, Liaw YF,. Clinical outcomes after interruption of entecavir therapy in HBeAg-negative chronic hepatitis B patients with compensated cirrhosis. Aliment Pharmacol Ther 2015; 42: 1182-91.
    • (2015) Aliment Pharmacol Ther , vol.42 , pp. 1182-1191
    • Chen, Y.C.1    Peng, C.Y.2    Jeng, W.J.3    Chien, R.N.4    Liaw, Y.F.5
  • 2
    • 84930847260 scopus 로고    scopus 로고
    • Current and future directions for treating hepatitis B virus infection
    • Tawada A, Kanda T, Yokosuka O,. Current and future directions for treating hepatitis B virus infection. World J Hepatol 2015; 7: 1541-52.
    • (2015) World J Hepatol , vol.7 , pp. 1541-1552
    • Tawada, A.1    Kanda, T.2    Yokosuka, O.3
  • 3
    • 79951528111 scopus 로고    scopus 로고
    • Association of intrahepatic cccDNA reduction with the improvement of liver histology in chronic hepatitis B patients receiving oral antiviral agents
    • Cheng PN, Liu WC, Tsai HW, Wu IC, Chang TT, Young KC,. Association of intrahepatic cccDNA reduction with the improvement of liver histology in chronic hepatitis B patients receiving oral antiviral agents. J Med Virol 2011; 83: 602-7.
    • (2011) J Med Virol , vol.83 , pp. 602-607
    • Cheng, P.N.1    Liu, W.C.2    Tsai, H.W.3    Wu, I.C.4    Chang, T.T.5    Young, K.C.6
  • 4
    • 84927513847 scopus 로고    scopus 로고
    • Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication
    • Dong C, Qu L, Wang H, Wei L, Dong Y, Xiong S,. Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication. Antiviral Res 2015; 118: 110-7.
    • (2015) Antiviral Res , vol.118 , pp. 110-117
    • Dong, C.1    Qu, L.2    Wang, H.3    Wei, L.4    Dong, Y.5    Xiong, S.6
  • 5
    • 84855712469 scopus 로고    scopus 로고
    • Molecular mechanisms underlying occult hepatitis B virus infection
    • Samal J, Kandpal M, Vivekanandan P,. Molecular mechanisms underlying occult hepatitis B virus infection. Clin Microbiol Rev 2012; 25: 142-63.
    • (2012) Clin Microbiol Rev , vol.25 , pp. 142-163
    • Samal, J.1    Kandpal, M.2    Vivekanandan, P.3
  • 6
    • 84940183673 scopus 로고    scopus 로고
    • Metabolism and function of hepatitis B virus cccDNA: Box drawings light down and leftmplications for the development of cccDNA-targeting antiviral therapeutics
    • Guo JT, Guo H,. Metabolism and function of hepatitis B virus cccDNA: box drawings light down and leftmplications for the development of cccDNA-targeting antiviral therapeutics. Antiviral Res 2015; 122: 91-100.
    • (2015) Antiviral Res , vol.122 , pp. 91-100
    • Guo, J.T.1    Guo, H.2
  • 7
    • 79951651043 scopus 로고    scopus 로고
    • HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy
    • Hosaka T, Suzuki F, Kobayashi M, et al,. HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy. Liver Int 2010; 30: 1461-70.
    • (2010) Liver Int , vol.30 , pp. 1461-1470
    • Hosaka, T.1    Suzuki, F.2    Kobayashi, M.3
  • 8
    • 84946018523 scopus 로고    scopus 로고
    • Current status of immunomodulatory therapy in chronic hepatitis B, fifty years after discovery of the virus: Search for the "magic bullet" to kill cccDNA
    • Zhang E, Kosinska A, Lu M, Yan H, Roggendorf M,. Current status of immunomodulatory therapy in chronic hepatitis B, fifty years after discovery of the virus: search for the "magic bullet" to kill cccDNA. Antiviral Res 2015; 123: 193-203.
    • (2015) Antiviral Res , vol.123 , pp. 193-203
    • Zhang, E.1    Kosinska, A.2    Lu, M.3    Yan, H.4    Roggendorf, M.5
  • 9
    • 84941686701 scopus 로고    scopus 로고
    • Anti-HBV drugs: Progress, unmet needs, and new hope
    • Kang L, Pan J, Wu J, Hu J, Sun Q, Tang J,. Anti-HBV drugs: progress, unmet needs, and new hope. Viruses 2015; 7: 4960-77.
    • (2015) Viruses , vol.7 , pp. 4960-4977
    • Kang, L.1    Pan, J.2    Wu, J.3    Hu, J.4    Sun, Q.5    Tang, J.6
  • 10
    • 84927950089 scopus 로고    scopus 로고
    • The hepatitis B virus ribonuclease H as a drug target
    • Tavis JE, Lomonosova E,. The hepatitis B virus ribonuclease H as a drug target. Antiviral Res 2015; 118: 132-8.
    • (2015) Antiviral Res , vol.118 , pp. 132-138
    • Tavis, J.E.1    Lomonosova, E.2

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.